Vuse is the current US market leader in e-cigarettes by dollar sales and the first brand to earn FDA marketing authorisation. It is owned by Reynolds American, part of British American Tobacco.
The devices
- Vuse Alto — the flagship. Flat rectangular pod system, USB-C charging, closed pods that snap into the top.
- Vuse Solo and Vuse Ciro — older pen-shaped cig-alikes. Lower dose, still sold as legacy products.
- Vuse Vibe and Vuse Alto Power Unit — larger-capacity variants.
Nicotine strengths
Alto pods are sold in 1.8%, 2.4%, and 5% (49 mg/mL) — the 5% is roughly cigarette-equivalent per puff. A 5% pod holds ~1.8 mL and ~88 mg of nicotine, larger than a Juul pod. Solo and Ciro deliver less nicotine per puff because they lack the salt-nicotine formulation.
FDA authorisation
In 2021 the FDA authorised Vuse Solo (tobacco flavour) as the first e-cigarette to pass the Premarket Tobacco Application process — the agency's determination that the benefits to adult smokers switching from cigarettes outweighed the risks to youth.
Since then:
- Vuse Alto tobacco pods received authorisation.
- Vuse Alto menthol pods received authorisation in 2024 (after litigation).
- Every non-tobacco, non-menthol flavour Vuse ever submitted has been denied.
What authorisation does not mean:
- It is not a safety endorsement.
- It is not "safer than Elf Bar" as a product claim.
- It applies to the specific product in the specific flavour submitted — not the brand as a whole.
Why Vuse dominates the counter
- Long distribution reach through Reynolds' cigarette network.
- Consistent hardware, unlike the churn of disposable brands.
- Legal to sell nationwide in tobacco and menthol, giving retailers cover.
If you're quitting Vuse
A daily 5% Alto pod is a heavy nicotine dependence. Treat it clinically like a pack-a-day smoker — see the NRT guide for matching a starting dose, and the medications guide if you want prescription options.



